Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 2
1954 2
1960 1
1963 1
1970 2
1980 1
1982 1
1983 1
1984 2
1985 1
1987 1
1989 2
1990 2
1991 3
1992 7
1993 3
1994 1
1995 2
1996 2
1997 3
1998 7
1999 5
2000 12
2001 11
2002 18
2003 14
2004 10
2005 16
2006 7
2007 4
2008 6
2009 12
2010 15
2011 16
2012 18
2013 15
2014 21
2015 7
2016 15
2017 12
2018 20
2019 16
2020 22
2021 12
2022 12
2023 8
2024 11
2025 15
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

369 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Culligan .
[No authors listed] [No authors listed] Anal Chem. 1970 Mar 1;42(3):34A. doi: 10.1021/ac60285a731. Anal Chem. 1970. PMID: 22738527 No abstract available.
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
Othman J, Potter N, Freeman SD, McCarthy N, Jovanovic J, Runglall M, Canham J, Thomas I, Johnson S, Gilkes A, Cavenagh J, Kottaridis P, Taussig D, Arnold C, Hemmaway C, Culligan D, Overgaard UM, Dennis M, Burnett AK, Russell NH, Dillon R. Othman J, et al. Blood. 2025 Oct 9;146(15):1862-1867. doi: 10.1182/blood.2025029556. Blood. 2025. PMID: 40768751 Clinical Trial.
Supramolecular calsequestrin complex.
Glover L, Quinn S, Ryan M, Pette D, Ohlendieck K. Glover L, et al. Eur J Biochem. 2002 Sep;269(18):4607-16. doi: 10.1046/j.1432-1033.2002.03160.x. Eur J Biochem. 2002. PMID: 12230573 Free article.
As recently demonstrated by overlay assays using calsequestrin-peroxidase conjugates, the major 63 kDa Ca(2+)-binding protein of the sarcoplasmic reticulum forms complexes with itself, and with junctin (26 kDa), triadin (94 kDa) and the ryanodine receptor (560 kDa) [Glover, L., …
As recently demonstrated by overlay assays using calsequestrin-peroxidase conjugates, the major 63 kDa Ca(2+)-binding protein of the sarcopl …
Early life nutrition.
Finn S, Culligan EP, Snelling WJ, Sleator RD. Finn S, et al. Sci Prog. 2018 Oct 1;101(4):332-359. doi: 10.3184/003685018X15360040523721. Epub 2018 Oct 8. Sci Prog. 2018. PMID: 30296969 Free PMC article. Review.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerlöf I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S; ENRICH investigators. Lewis DJ, et al. Lancet. 2025 Oct 25;406(10514):1953-1968. doi: 10.1016/S0140-6736(25)01432-1. Epub 2025 Oct 3. Lancet. 2025. PMID: 41052510 Free PMC article. Clinical Trial.
Malnutrition in the elderly.
Corcoran C, Murphy C, Culligan EP, Walton J, Sleator RD. Corcoran C, et al. Sci Prog. 2019 Jun;102(2):171-180. doi: 10.1177/0036850419854290. Sci Prog. 2019. PMID: 31829839 Free PMC article.
Pathology in Practice.
Culligan CM, Craig LE. Culligan CM, et al. J Am Vet Med Assoc. 2020 Aug 15;257(4):383-385. doi: 10.2460/javma.257.4.383. J Am Vet Med Assoc. 2020. PMID: 32715883 Free article. No abstract available.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Free PMC article. Clinical Trial.
369 results